Neurológia pre prax 6/2021

Long-term data of multiple sclerosis treatment with ocrelizumab – eficacy, safety and clinical experience

Both T lymphocytes and B lymphocytes are involved in the patogenesis of multiple sclerosis (MS). Ocrelizumab is a monoclonal antibody that targets B lymphocytes. It is indicated for the treatment of relapsing remitting MS (RRMS) as well as for the treatment of primary progressive MS (PPMS). While there are several possibilities for immunomodulatory therapy for the treatment of RRMS, until recently, there was no possibility of influencing the course of PPMS by immunomodulatory treatment. Ocrelizumab is currently the only registered DMD therapy for the treatment of PPRS in the Czech Republic. In general, it is well tolerated with minimal adverse events.

Keywords: ocrelizumab, primary progressive multiple sclerosis, relaps remmiting multiple sclerosis, B lymphocytes